The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...

According to the study, participants taking Zepbound lost an average of 20.2% of their starting weight after 72 weeks, ...

The weight-loss market began feeling some growing pains as the year ended, creating more wariness for the upcoming year. For ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

Zepbound, as expected, was more effective in promoting weight loss. Eli Lilly's Zepbound drug ... according to GlobalData, a leading data and analytics company. It has been a year since the ...

Zepbound, Eli Lilly's (LLY) weekly injectable weight-loss treatment, provides up to 24% weight loss, while Wegovy from Novo Nordisk provides up to 16%. Novo's most recent clinical trial data for ...

This top healthcare company trades at 13 times forward earnings. It has a diverse portfolio of products, yields 3.6% at the ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...

The rise of GLP-1 medications has transformed the way Americans lose weight, and the data supports that ... some GLP-1 medications like Wegovy and Zepbound are FDA-approved for weight loss ...